Partial
Not Aligned
Patient Risk:
Moderate
Summary
Several safety-related claims align with the provided label text (notably lactic acidosis risk concepts and some discontinuation/urgency framing), but many statements are unsupported by the supplied FDA label excerpts (e.g., specific adverse effects like headache/upper respiratory symptoms/pancreatitis/alleged dose-timing adjustments), and multiple details are either generalized beyond the provided label or not evidenced in the provided sections.
Category Scores
Accurate Statements
Kazano can cause signs of lactic acidosis, described as a rare but serious metformin-related condition, with nonspecific symptoms (e.g., malaise/myalgias/abdominal pain/respiratory distress/increased somnolence can occur) and severe cases can include bradyarrhythmias or hypotension; Metformin-associated lactic acidosis requires prompt action.
Supported by 5.1 Lactic Acidosis: postmarketing cases with subtle onset and nonspecific symptoms (malaise, myalgias, abdominal pain, respiratory distress, increased somnolence) and severe acidosis with hypothermia, hypotension, resistant bradyarrhythmias; 5.1 also emphasizes patient/family education and prompt discontinuation and hospital supportive measures.
Risk of metformin-related lactic acidosis is higher with reduced kidney function and the risk increases with severity of renal impairment.
Supported by 5.1 Renal Impairment subsection and 8.6 Renal Impairment (metformin substantially excreted by kidney; risk increases with degree of renal impairment).
Kidney function is typically checked before and during therapy with Kazano.
Supported by 2.2 (assess renal function prior to initiation and periodically thereafter) and 5.1 Renal Impairment (obtain eGFR before initiating; obtain eGFR at least annually; more frequently in higher-risk patients).
If symptoms of allergy, pancreatitis, or lactic acidosis develop, urgent medical help should be sought.
Partially supported: 5.1 Lactic Acidosis instructs educating patients to discontinue KAZANO and report symptoms of lactic acidosis to healthcare provider; the label excerpts provided do not support pancreatitis/allergy urgency wording specifically within the supplied text.
Unsupported Statements
Kazano is a combination of sitagliptin and metformin used to treat type 2 diabetes.
The provided FDA label text excerpts identify the fixed-dose combination as alogliptin and metformin HCl; no supplied text supports sitagliptin. The provided excerpts also do not state the indication wording.
Common side effects of Kazano include gastrointestinal effects from metformin such as nausea, vomiting, diarrhea, stomach upset, and loss of appetite.
The supplied label excerpts do not list these as 'common side effects' or provide a gastrointestinal adverse reaction list.
Sitagliptin can cause side effects such as headache.
Unsupported: the supplied label excerpts do not mention headache or any sitagliptin adverse effects; also the drug contains alogliptin, not sitagliptin, per the provided label header.
Sitagliptin can cause upper respiratory symptoms such as stuffy or runny nose and sore throat.
Unsupported: no supplied label excerpt supports these specific symptoms as sitagliptin adverse effects; the provided excerpts do not cover upper respiratory adverse events.
Kazano can cause severe allergic reactions with rash, hives, swelling of the face or throat, and trouble breathing.
Unsupported in the provided excerpts: the contraindications reference history of hypersensitivity and cites 5.4 and 6.2, but the supplied text does not describe the specific allergic reaction manifestations (rash/hives/face/throat/trouble breathing).
Kazano can cause pancreatitis, with symptoms that can include severe abdominal pain often with nausea and vomiting.
Unsupported by the provided excerpts: pancreatitis is not discussed in the included label sections.
Kazano can cause low blood sugar (hypoglycemia), especially if used together with other glucose-lowering medicines.
Unsupported: hypoglycemia is not addressed in the provided label excerpts.
Hypoglycemia risk is increased when Kazano is combined with insulin or a sulfonylurea.
Unsupported: no supplied label excerpt addresses hypoglycemia risk with insulin or sulfonylureas.
Gastrointestinal side effects are among the most common with metformin-containing therapies.
Unsupported by supplied excerpts: no provided text ranks frequency of GI side effects.
People may experience diarrhea, nausea, vomiting, or abdominal discomfort with metformin-containing therapies, particularly when starting treatment or increasing the dose.
Unsupported: the provided excerpts do not contain dosing-initiation/uptitration-related GI adverse reaction statements.
Most stomach-related side effects tend to appear early in treatment and may lessen as the body adjusts.
Unsupported: no such temporal pattern statement exists in the provided excerpts.
Serious side effects like pancreatitis or lactic acidosis are uncommon but can occur at any time during use.
Partially supported regarding lactic acidosis being serious, but frequency ('uncommon') and 'can occur at any time' are not supported by the supplied excerpts; pancreatitis frequency is entirely unsupported.
If mild stomach symptoms occur, clinicians may adjust the dose or timing to reduce effects.
Unsupported: the provided label excerpts do not provide guidance to adjust dose/timing for mild stomach symptoms.
If symptoms of allergy, pancreatitis, or lactic acidosis develop, urgent medical help should be sought.
Only lactic acidosis is explicitly supported in the provided excerpts (5.1). The provided text does not support urgency guidance for allergy or pancreatitis.
Risk of metformin-related lactic acidosis is increased by conditions that lower oxygen delivery or increase medication buildup.
Partially supported: hypoxic states are discussed in 5.1, but 'increase medication buildup' is not explicitly described in the provided excerpts (beyond accumulation from renal impairment).
Examples of conditions that can increase lactic acidosis risk include significant kidney impairment, severe infection, dehydration, heavy alcohol use, or some acute illnesses.
Partially supported: renal impairment and alcohol are supported; severe infection/dehydration/acute illnesses are not explicitly listed in the provided excerpts.
Risk of metformin-related lactic acidosis is increased by conditions that lower oxygen delivery or increase medication buildup.
As above, only hypoxic states and renal impairment/accumulation are explicitly supported in the excerpts.
Contradictions
Important Omissions
Renal contraindication threshold: KAZANO is contraindicated in patients with eGFR < 30 mL/min/1.73 m^2, and not recommended for eGFR 30–60 due to requiring a lower alogliptin dose than available in the fixed combination product.
Importance:
High
Label-directed action and setting for suspected lactic acidosis: discontinue KAZANO and institute general supportive measures in a hospital setting, and prompt hemodialysis is recommended.
Importance:
High
Contrast procedure-specific instructions: stop at time of or prior to iodinated contrast imaging for certain eGFR ranges and risk histories; reassess eGFR 48 hours after and restart if stable.
Importance:
Moderate
Alcohol warning is supported in the label, but the response does not include label-backed counseling against excessive alcohol intake while receiving KAZANO.
Importance:
Moderate
Specific drug-interaction examples listed in the label excerpts (e.g., carbonic anhydrase inhibitors such as topiramate/zonisamide/acetazolamide/dichlorphenamide; and metformin clearance inhibitors like ranolazine/vandetanib/dolutegravir/cimetidine).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple lactic acidosis-related claims are directionally consistent, but key label-specific safety requirements (explicit eGFR contraindication/not recommended ranges, hospital-based supportive measures and hemodialysis, and contrast procedure withholding/restart timing) are omitted. Several other statements are unsupported or inaccurate (e.g., sitagliptin instead of alogliptin), which could misinform risk communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Drug ingredient/side-effect attribution errors (sitagliptin used instead of alogliptin) and omission of critical label-specific lactic acidosis management and renal/contrast restrictions.
Suggested Improvement
Replace sitagliptin-based statements with alogliptin/metformin-specific label content; add the label’s eGFR contraindication (<30) and not-recommended (30–59) guidance for fixed-dose product; include label-directed steps for suspected lactic acidosis (discontinue in hospital setting and prompt hemodialysis) and iodinated contrast withholding/restart instructions; restrict adverse reaction lists to those supported in the provided label excerpts.